

Levonorgestrel IUD potentially cost-effective in obese women

September 12 2016



(HealthDay)—For obese women, the levonorgestrel intrauterine device



(IUD) could be cost-effective for preventing endometrial cancer deaths, according to a study published in the October issue of *Obstetrics* & *Gynecology*.

Joseph A. Dottino, M.D., M.P.H., from the Duke University Medical Center in Durham, N.C., and colleagues used a modified Markov model to compare IUD placement at age 50 with usual care among <u>women</u> with a BMI \geq 40 or \geq 30 kg/m². The authors incorporated the effect of obesity on incidence and survival. The IUD was assumed to confer a 50 percent reduction in the incidence of endometrial cancer over five years; costs of IUD and cancer care were included in the analyses.

The researchers found that the IUD strategy was costlier and more effective than usual care for a 50-year-old with BMI \geq 40 kg/m², with a cost-effectiveness ratio of \$74,707 per year of life saved. Assuming the protective effect of the levonorgestrel IUD was 10 years, the incremental cost-effectiveness ratio would decrease to \$37,858 per life-year saved. In women with BMIs of \geq 40 kg/m² or costs less than \$500, a levonorgestrel IUD that reduces cancer incidence by at least 68 percent would be cost-effective. The incremental cost-effectiveness ratio of IUD strategy was \$137,223 per life-year saved compared with usual care for women with BMI \geq 30 kg/m².

"The levonorgestrel IUD is a potentially cost-effective strategy for prevention of deaths from endometrial <u>cancer</u> in <u>obese women</u>," the authors write.

More information: <u>Full Text (subscription or payment may be</u> <u>required)</u>

Copyright © 2016 HealthDay. All rights reserved.



Citation: Levonorgestrel IUD potentially cost-effective in obese women (2016, September 12) retrieved 4 May 2024 from <u>https://medicalxpress.com/news/2016-09-levonorgestrel-iud-potentially-cost-effective-</u>

<u>obese.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.